Podophyllin office therapy against condyloma should be abandoned

Abstract

Podophyllin, a crude plant extract with low efficacy, high toxicity, and a serious mutagenicity profile does not comply with the WHO guidelines for plant derived treatments and should be removed from clinical treatment protocols. Home treatment with pharmaceutical products based on podophyllotoxin - the purified, standardised active antiwart ingredient of podophyllin - represents safe and effective first line therapy for patients with anogenital warts.